Literature DB >> 19592011

Dexamethasone alters the hepatic inflammatory cellular profile without changes in matrix degradation during liver repair following biliary decompression.

Christopher S Muratore1, Mark W Harty, Elaine F Papa, Thomas F Tracy.   

Abstract

BACKGROUND: Biliary atresia is characterized by extrahepatic bile duct obliteration along with persistent intrahepatic portal inflammation. Steroids are standard in the treatment of cholangitis following the Kasai portoenterostomy, and were advocated for continued suppression of the ongoing immunologic attack against intrahepatic ducts. Recent reports, however, have failed to demonstrate an improved patient outcome or difference in the need for liver transplant in postoperative patients treated with a variety of steroid regimes compared with historic controls. In the wake of progressive liver disease despite biliary decompression, steroids are hypothesized to suppress inflammation and promote bile flow without any supporting data regarding their effect on the emerging cellular and molecular mechanisms of liver repair. We have previously shown in a reversible model of cholestatic injury that repair is mediated by macrophages, neutrophils, and specific matrix metalloproteinase activity (MMP8); we questioned whether steroids would alter these intrinsic mechanisms.
METHODS: Rats underwent biliary ductal suspension for 7 d, followed by decompression. Rats were treated with IV dexamethasone or saline at the time of decompression. Liver tissue obtained at the time of decompression or after 2 d of repair was processed for morphometric analysis, immunohistochemistry, and quantitative RT-PCR.
RESULTS: There was a dramatic effect of dexamethasone on the inflammatory component with the initiation of repair. Immunohistochemistry revealed a reduction of both ED1+ hepatic macrophages and ED2+Kupffer cells in repair compared with saline controls. Dexamethasone treatment also reduced infiltrating neutrophils by day 2. TNF-alpha expression, increased during injury in both saline and dexamethasone groups, was markedly reduced by dexamethasone during repair (day 2) whereas IL-6, IL-10, and CINC-1 remained unchanged compared with saline controls. Dexamethasone reduced both MMP8 and TIMP1 expression by day 2, whereas MMP9, 13, and 14 were unchanged compared with sham controls. Despite substantial cellular and molecular changes during repair, collagen resorption was the same in both groups
CONCLUSION: Dexamethasone has clear effects on both the hepatic macrophage populations and infiltrating neutrophils following biliary decompression. Altered MMP and TIMP gene expression might suggest that steroids have the potential to modify matrix metabolism during repair. Nevertheless, successful resorption of collagen fibrosis proceeded presumably through other MMP activating mechanisms. We conclude that steroids do not impede the rapid intrinsic repair mechanisms of matrix degradation required for successful repair.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19592011      PMCID: PMC2749887          DOI: 10.1016/j.jss.2009.04.016

Source DB:  PubMed          Journal:  J Surg Res        ISSN: 0022-4804            Impact factor:   2.192


  25 in total

1.  Primer3 on the WWW for general users and for biologist programmers.

Authors:  S Rozen; H Skaletsky
Journal:  Methods Mol Biol       Date:  2000

2.  Immunosuppression as adjuvant therapy for biliary atresia.

Authors:  P W Dillon; E Owings; R Cilley; D Field; A Curnow; K Georgeson
Journal:  J Pediatr Surg       Date:  2001-01       Impact factor: 2.545

3.  CD8+ T cells infiltrating into bile ducts in biliary atresia do not appear to function as cytotoxic T cells: a clinicopathological analysis.

Authors:  A F Ahmed; H Ohtani; M Nio; N Funaki; S Shimaoka; H Nagura; R Ohi
Journal:  J Pathol       Date:  2001-03       Impact factor: 7.996

4.  A model of reversible obstructive jaundice in the rat.

Authors:  M C Posner; M E Burt; M D Stone; B L Han; R S Warren; N A Vydelingum; M F Brennan
Journal:  J Surg Res       Date:  1990-03       Impact factor: 2.192

5.  Bile duct and liver pathology in biliary atresia.

Authors:  J E Haas
Journal:  World J Surg       Date:  1978-09       Impact factor: 3.352

Review 6.  Biliary atresia.

Authors:  M Nio; R Ohi
Journal:  Semin Pediatr Surg       Date:  2000-11       Impact factor: 2.754

7.  The pharmacokinetic and biological activity profile of dexamethasone targeted to sinusoidal endothelial and Kupffer cells.

Authors:  Barbro N Melgert; Betty Weert; Huub Schellekens; Dirk K F Meijer; Klaas Poelstra
Journal:  J Drug Target       Date:  2003-01       Impact factor: 5.121

8.  Intrahepatic bile duct loss in biliary atresia despite portoenterostomy: a consequence of ongoing obstruction?

Authors:  G W Nietgen; J P Vacanti; A R Perez-Atayde
Journal:  Gastroenterology       Date:  1992-06       Impact factor: 22.682

9.  Hepatic macrophages promote the neutrophil-dependent resolution of fibrosis in repairing cholestatic rat livers.

Authors:  Mark W Harty; Elaine F Papa; Hannah M Huddleston; Ezekiel Young; Samantha Nazareth; Charles A Riley; Grant A Ramm; Stephen H Gregory; Thomas F Tracy
Journal:  Surgery       Date:  2008-05       Impact factor: 3.982

Review 10.  High-dose steroids, ursodeoxycholic acid, and chronic intravenous antibiotics improve bile flow after Kasai procedure in infants with biliary atresia.

Authors:  Rebecka L Meyers; Linda S Book; Molly A O'Gorman; W Daniel Jackson; Richard E Black; Dale G Johnson; Michael E Matlak
Journal:  J Pediatr Surg       Date:  2003-03       Impact factor: 2.545

View more
  2 in total

1.  Dexamethasone pretreatment attenuates lung and kidney injury in cholestatic rats induced by hepatic ischemia/reperfusion.

Authors:  Liangyi Zhou; Xiangqing Yao; Yanling Chen
Journal:  Inflammation       Date:  2012-02       Impact factor: 4.092

2.  Hepatocytes buried in the cirrhotic livers of patients with biliary atresia proliferate and function in the livers of urokinase-type plasminogen activator-NOG mice.

Authors:  Hiroshi Suemizu; Kazuaki Nakamura; Kenji Kawai; Yuichiro Higuchi; Mureo Kasahara; Junichiro Fujimoto; Akito Tanoue; Masato Nakamura
Journal:  Liver Transpl       Date:  2014-08-04       Impact factor: 5.799

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.